KLK3 and posterior cortical atrophy: The general consensus is that AS is the preferred treatment for men with a life expectancy of >10 years and low-risk PCa (GG1 with PSA < 10 ng/mL and ≤T2a), and an optional treatment for favourable intermediate-risk (GG1 with PSA < 20 ng/mL and ≤T2a, or, i.e., GG1 with PSA < 10 ng/mL and ≤T2a with low tumour volume).